The ongoing study of the Baiobit® sensor for gait assessment in stroke survivors could disrupt the stroke rehabilitation market by providing a cost-effective alternative to traditional systems. Pharma companies focused on neurology should monitor the results closely to assess potential impacts on their product strategies and market positioning. Regulatory context from FDA (BsUFA II: Assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act) supports the near-term read. Assessment grounded in 5 ranked evidence items (2 high-relevance).